NEWS

Virginia’s biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. Since 2025, life sciences companies have committed $10B+ in newly announced investments in Virginia to bolster research and development, expand manufacturing, and create jobs across the state.   In Virginia: At least three new, major manufacturing facilities from Eli Lilly  in Goochland County, AstraZeneca  in Albemarle and Merck  in Elkton 1,750 perma

The Administration has made lowering health care costs a top priority, a commendable goal.  Yet the proposed most-favored nation (MFN) policy would almost certainly undermine the ability to keep that promise. By disincentivizing investment in the life sciences sector, MFN could cost the U.S. its edge in global biopharmaceutical leadership. Hear what the experts are saying:

A groundbreaking report quantifies what patients and their families have long understood: American medical innovation is making life better for all of us. This new analysis, conducted by researchers at the University of Chicago and supported by the U.S. Chamber of Commerce, estimates medical breakthroughs delivered $167.5 trillion in societal value to the United States. How Innovation Delivers The researchers looked at innovations in four major disease areas – HIV, heart di

Across global health systems, policymakers face a familiar but increasingly urgent challenge: managing rising health care costs without undermining the innovation and intellectual property systems that make future therapies possible.   Biopharmaceutical research is inherently long term . It requires substantial upfront investment and a stable intellectual property (IP) framework to ensure that successful products generate returns. When this balance is disrupted, the resulting

Last week, We Work For Health Executive Director Dan Leonard participated in a panel at the HealthCare Institute of New Jersey's (HINJ) 2026 Pulse: Saving Lives Globally, Driving Our Economy Locally  – a seminar designed to inform industry leaders, policymakers, and stakeholders about the state of New Jersey's life sciences sector and its leading role in advancing global health. The event took place at Middlesex College in Edison, New Jersey. New Jersey Governor Mikie Sherril

America remains the global leader in biopharmaceutical research and development, but an alarming climb from China over the past decade warrants a strategic response from U.S. policymakers, according to new research and recommendations from the Information Technology and Innovation Foundation.  The report compares private-sector R&D investments between U.S.- and China-headquartered firms across nine advanced industries, including pharmaceuticals and biotechnology, revealing a

America's biopharmaceutical leadership has never been more contested – or more consequential. As policymakers in Washington consider proposals like most favored nation (MFN), which would tie U.S. prices to European benchmarks, a critical question emerges: What actually happens when a country chooses cost containment over innovation?   Europe has lived that story.   The U.S. cannot afford to ignore how it ends.  On March 5, We Work For Health convened experts, industry leaders

We Work For Health's Executive Director Dan Leonard recently sat down with Dr. Robert Popovian, Chief Science Policy Officer at the Global Healthy Living Foundation and founder of Conquest Advisors, to discuss what's actually happening at the pharmacy counter now that the first Medicare-negotiated drug prices under the Inflation Reduction Act have taken effect.  Nearly two months into implementation, the picture emerging is far more complicated than the government's promises